Low-dose aspirin is not an alternative to any other treatment. Patients with cancer should however raise the topic of aspirin with their healthcare team and enquire whether or not low-dose aspirin is likely to be helpful to them.
The most recent ASPREE report (1) can be set in broader context. A systematic review and meta-analysis of primary prevention trials, which included ASPREE, found aspirin gave a non-significant reduction of all-cause mortality by 3% Read more
Harnessing aspirin’s potential to improve prevention, treatment, and healthy ageing across the cancer journey. This aligns with the latest research on cancer: recommendations for prevention and innovation that could greatly influence future therapies. Based on Read more
by The Welsh Aspirin Group Peter Elwood, Gareth Morgan, Richard Adams, Christine Delon, Marcus Longley, Simon Noble, Janet Pickering, Majd Protty, John Watkins, Anna Yeatman Corresponding author: Gareth Morgan ABSTRACT: Aspirin is a remarkable drug Read more
Myeloproliferative neoplasms (MPN’s) are a group of blood cancers. MPN’s are bone marrow disorders which results in an excess of blood cells. As a result, these blood cancers are associated with risks of clots and Read more
Abstract There is a growing body of evidence that aspirin could be helpful in the treatment of cancer. In this paper, ten randomised controlled trials are reviewed covering more than 8,000 patients with several different Read more